EP0909323B1
(fr)
|
1996-01-04 |
2007-02-28 |
Novartis Vaccines and Diagnostics, Inc. |
Bacterioferritine de helicobacter pilori
|
CA2881568C
(fr)
|
2000-10-27 |
2019-09-24 |
Novartis Vaccines And Diagnostics, Inc. |
Acides nucleiques et proteines derives des groupes de streptocoques a et b
|
AU2002227365A1
(en)
|
2000-12-07 |
2002-06-18 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
MY134424A
(en)
*
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
CA2476626A1
(fr)
|
2002-02-20 |
2003-08-28 |
Chiron Corporation |
Microparticules comprenant des molecules adsorbees qui contiennent polypeptides
|
US8518694B2
(en)
|
2002-06-13 |
2013-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
SI2351579T1
(sl)
|
2002-10-11 |
2017-05-31 |
Glaxosmithkline Biologicals Sa |
Polipeptidna cepiva za široko zaščito proti hipervirulentnim meningokoknim linijam
|
US20070059329A1
(en)
|
2002-11-15 |
2007-03-15 |
Nathalie Norais |
Unexpected surface proteins in meningococcus
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
WO2004060396A2
(fr)
|
2002-12-27 |
2004-07-22 |
Chiron Corporation |
Immunogenes contenant des compositions de phospholipide
|
CN101926988B
(zh)
|
2003-01-30 |
2014-06-04 |
诺华疫苗和诊断有限公司 |
抗多种脑膜炎球菌血清组的可注射性疫苗
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
CA2522379C
(fr)
|
2003-04-10 |
2012-10-23 |
Chiron Corporation |
Le coronavirus du syndrome respiratoire aigu grave
|
US9107831B2
(en)
|
2003-06-02 |
2015-08-18 |
Novartis Vaccines And Diagonstics, Inc. |
Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
ATE506963T1
(de)
|
2003-10-02 |
2011-05-15 |
Novartis Vaccines & Diagnostic |
Kombinationsimpfstoffe gegen meningitis
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
WO2005107797A1
(fr)
|
2004-03-09 |
2005-11-17 |
Chiron Corporation |
Vaccins antigrippaux
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
PL1740217T3
(pl)
|
2004-04-30 |
2012-03-30 |
Novartis Ag |
Szczepienie koniugatem meningokokowym
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
CA2567446C
(fr)
|
2004-05-21 |
2018-01-02 |
Chiron Corporation |
Vecteurs d'alphavirus pour vaccins contre pathogenes respiratoires
|
EP1765313A2
(fr)
|
2004-06-24 |
2007-03-28 |
Novartis Vaccines and Diagnostics, Inc. |
Composes utilises pour l'immunopotentialisation
|
WO2006078318A2
(fr)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
PT2682126T
(pt)
|
2005-01-27 |
2017-02-28 |
Children`S Hospital & Res Center At Oakland |
Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
HUE030881T2
(en)
|
2005-02-18 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Meningitis / sepsis-associated escherichia coli proteins and nucleic acids
|
WO2007015441A1
(fr)
|
2005-08-01 |
2007-02-08 |
Hisamitsu Pharmaceutical Co., Inc. |
Adjuvant ou préparation pharmaceutique pour administration transdermique ou transmucosale
|
JP2009511636A
(ja)
|
2005-10-18 |
2009-03-19 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
JP2009514838A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
細胞培養物において増殖されたインフルエンザウイルスから調製された非ビリオン抗原を含むアジュバントワクチン
|
WO2007052057A2
(fr)
*
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Voies d'administration pour sensibilisation/stimulation par des vaccins contre la grippe
|
EP2360175B1
(fr)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Particules de type virus (vlps) de norovirus et de sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
DK2478916T3
(da)
|
2006-01-27 |
2020-06-15 |
Seqirus Uk Ltd |
Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
|
US8535683B2
(en)
|
2006-03-22 |
2013-09-17 |
Abbott Biologicals B.V. |
Intranasal or inhalational administration of virosomes
|
ES2376492T3
(es)
|
2006-03-23 |
2012-03-14 |
Novartis Ag |
Compuestos de imidazoquinoxalina como inmunomoduladores.
|
CA2646349A1
(fr)
*
|
2006-03-24 |
2007-10-04 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Stockage de vaccins antigrippaux sans refrigeration
|
WO2007126825A2
(fr)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Immunisation mucosale et parentérale combinée contre le vih
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
AU2007285484B2
(en)
|
2006-08-16 |
2013-05-02 |
Novartis Ag |
Immunogens from uropathogenic Escherichia coli
|
ES2694805T7
(es)
|
2006-09-11 |
2021-10-21 |
Seqirus Uk Ltd |
Fabricación de vacunas contra virus de la gripe sin usar huevos
|
SG177141A1
(en)
|
2006-12-06 |
2012-01-30 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EP2123296B1
(fr)
*
|
2007-01-31 |
2019-05-22 |
Hisamitsu Pharmaceutical Co., Inc. |
Adjuvant pour administration transdermique ou transmucosale et preparation pharmaceutique le contenant
|
EP2185191B1
(fr)
|
2007-06-27 |
2012-09-12 |
Novartis AG |
Vaccins antigrippaux à faible teneur en additifs
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
US8815253B2
(en)
|
2007-12-07 |
2014-08-26 |
Novartis Ag |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
NZ601543A
(en)
|
2007-12-21 |
2013-03-28 |
Novartis Ag |
Mutant forms of streptolysin o
|
EP2886551A3
(fr)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Polypeptides fHbp méningococciques
|
US9511131B2
(en)
|
2008-03-10 |
2016-12-06 |
Children's Hospital & Research Center Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
NZ592977A
(en)
|
2008-12-09 |
2013-01-25 |
Pfizer Vaccines Llc |
IgE CH3 PEPTIDE VACCINE
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
JP5642712B2
(ja)
|
2009-02-10 |
2014-12-17 |
ノバルティス アーゲー |
少ない量のスクアレンを含むインフルエンザワクチン
|
RU2011140508A
(ru)
|
2009-03-06 |
2013-04-20 |
Новартис Аг |
Антигены хламидии
|
CN109248313B
(zh)
|
2009-04-14 |
2023-01-17 |
葛兰素史密丝克莱恩生物有限公司 |
用于免疫接种以抵御金黄色葡萄球菌的组合物
|
KR101450958B1
(ko)
|
2009-04-30 |
2014-10-15 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
폐렴구균 백신 및 그의 용도
|
EP2442826B1
(fr)
|
2009-06-15 |
2015-07-08 |
National University of Singapore |
Vaccin contre l'influenza, composition, et procedes d'utilisation
|
JP2012532600A
(ja)
|
2009-07-07 |
2012-12-20 |
ノバルティス アーゲー |
保存された大腸菌免疫原
|
ES2918381T3
(es)
|
2009-07-15 |
2022-07-15 |
Glaxosmithkline Biologicals Sa |
Composiciones de proteína F de VRS y métodos para producir las mismas
|
PT2464658E
(pt)
|
2009-07-16 |
2015-01-14 |
Novartis Ag |
Imunogénios de escherichia coli desintoxicados
|
NZ618391A
(en)
|
2009-07-30 |
2015-07-31 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
EP2470204B1
(fr)
|
2009-08-27 |
2015-12-16 |
GlaxoSmithKline Biologicals SA |
Polypeptides hybrides contenant des séquences fhbp à méningocoques
|
KR101660578B1
(ko)
|
2009-09-03 |
2016-09-27 |
화이자 백신스 엘엘씨 |
Pcsk9 백신
|
CA2779798C
(fr)
|
2009-09-30 |
2019-03-19 |
Novartis Ag |
Conjugaison de polysaccharides capsulaires de staphylococcus aureus de type 5 et de type 8
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
BR112012010531A2
(pt)
|
2009-10-27 |
2019-09-24 |
Novartis Ag |
"polipeptídeos de modificação meningocócica fhbp"
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011077309A2
(fr)
|
2009-12-22 |
2011-06-30 |
Pfizer Vaccines Llc |
Compositions de vaccin
|
EP2519265B1
(fr)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Immunogènes de polysaccharide conjugués à des protéines porteuses de e. coli
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2552942B1
(fr)
|
2010-03-30 |
2017-12-27 |
Children's Hospital & Research Center at Oakland |
Protéines de liaison du facteur h (fhbp) avec des propriétés altérées et leurs procédés d'utilisation
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
CA2796314A1
(fr)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Compositions de benzonapthyridine et leurs utilisations
|
EP2575868A1
(fr)
|
2010-06-07 |
2013-04-10 |
Pfizer Vaccines LLC |
Vaccin peptidique ige ch3
|
WO2011154863A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Inc. |
Peptides her-2 et vaccins
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
US20130171185A1
(en)
|
2010-07-06 |
2013-07-04 |
Ethan Settembre |
Norovirus derived immunogenic compositions and methods
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(fr)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Epitopes rrgb de pneumocoque et combinaisons de variantes
|
US20130315959A1
(en)
|
2010-12-24 |
2013-11-28 |
Novartis Ag |
Compounds
|
PT2667892T
(pt)
|
2011-01-26 |
2019-06-07 |
Glaxosmithkline Biologicals Sa |
Regime de imunização contra o vsr
|
WO2012131504A1
(fr)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Vaccin à base de pcsk9
|
PT2707385T
(pt)
|
2011-05-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
Antigénios de f de rsv pré-fusão
|
JP2014520807A
(ja)
|
2011-07-06 |
2014-08-25 |
ノバルティス アーゲー |
免疫原性組成物およびその使用
|
EP2729165B1
(fr)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Compositions de combinaisons immunogènes et utilisations de celles-ci
|
US10030052B2
(en)
|
2011-07-25 |
2018-07-24 |
Glaxosmithkline Biologicals Sa |
Parvovirus Vp1 unique region polypeptides and compositions thereof
|
EP2659906A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659907A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP3563865A3
(fr)
|
2012-05-04 |
2019-12-04 |
Pfizer Inc |
Régimes immunothérapeutiques basés sur des antigènes associés à la prostate et un vaccin
|
SG11201407440WA
(en)
|
2012-05-22 |
2014-12-30 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
WO2014005958A1
(fr)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Compositions immunogéniques et leurs utilisations
|
EA201590427A1
(ru)
|
2012-10-02 |
2015-09-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Нелинейные сахаридные конъюгаты
|
RU2015106791A
(ru)
|
2012-10-03 |
2016-11-20 |
Глэксосмитиклайн Байолоджикалз Са |
Иммуногенные композиции
|
AU2013351182C1
(en)
|
2012-11-30 |
2018-11-08 |
Glaxosmithkline Biologicals Sa |
Pseudomonas antigens and antigen combinations
|
CA2909586C
(fr)
|
2013-05-15 |
2021-08-31 |
The Governors Of The University Of Alberta |
Vaccins contre le vhc e1e2 et procedes d'utilisation desdits vaccins
|
WO2015064710A1
(fr)
|
2013-10-31 |
2015-05-07 |
久光製薬株式会社 |
Composition adjuvante, préparation adjuvante la contenant et kit
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
AU2015208821B2
(en)
|
2014-01-21 |
2017-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(fr)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
|
CA3212723A1
(fr)
|
2014-07-23 |
2016-01-28 |
Peter T. Beernink |
Variants de proteines de liaison au facteur h et procedes d'utilisation de ceux-ci
|
FI3244917T3
(fi)
|
2015-01-15 |
2023-05-25 |
Pfizer |
Immunogeenisiä koostumuksia pneumokokkirokotteissa käytettäväksi
|
US10576131B2
(en)
|
2015-06-03 |
2020-03-03 |
Affiris Ag |
IL-23-p19 vaccines
|
WO2017005851A1
(fr)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccins pour le traitement et la prévention de maladies médiées par ige
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
CA3005524C
(fr)
|
2015-11-20 |
2023-10-10 |
Pfizer Inc. |
Compositions immunogenes destinees a etre utilisees dans des vaccins pneumococciques
|
CA2954892A1
(fr)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogenes derives d'antigenes associes a une tumeur ou des modules d'acide nucleique codant les immunogenes
|
DK3570879T3
(da)
|
2017-01-20 |
2022-04-11 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
WO2019173438A1
(fr)
|
2018-03-06 |
2019-09-12 |
Stc. Unm |
Compositions et méthodes pour faire baisser les triglycérides sériques
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
JP2022528158A
(ja)
|
2019-04-10 |
2022-06-08 |
ファイザー・インク |
コンジュゲート化莢膜糖抗原を含む免疫原性組成物、それを含むキットおよびその使用
|
IL292494A
(en)
|
2019-11-01 |
2022-06-01 |
Pfizer |
Preparations of Escherichia coli and their methods
|
AU2021224078B2
(en)
|
2020-02-21 |
2024-01-18 |
Pfizer Inc. |
Purification of saccharides
|
EP4107170A2
(fr)
|
2020-02-23 |
2022-12-28 |
Pfizer Inc. |
Escherichia coli compositions d'et méthodes associées
|
TW202227467A
(zh)
|
2020-10-27 |
2022-07-16 |
美商輝瑞大藥廠 |
大腸桿菌組合物及其方法
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
TWI750929B
(zh)
*
|
2020-12-02 |
2021-12-21 |
林建宏 |
氣霧免疫用之溫敏型佐劑及其製作方法
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(fr)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
|
MX2023009728A
(es)
|
2021-02-19 |
2023-08-30 |
Sanofi Pasteur Inc |
Vacuna recombinante meningococica b.
|
WO2022234483A1
(fr)
|
2021-05-04 |
2022-11-10 |
King Abdullah University Of Science And Technology |
Compositions immuogéniques de protéine n mutante de sars-cov-2 et gène et procédés d'utilisation associés
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
PE20240090A1
(es)
|
2021-05-28 |
2024-01-16 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
|
WO2023079528A1
(fr)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions appropriées pour une utilisation dans un procédé pour déclencher une immunité protectrice croisée contre des coronavirus
|
WO2023079529A1
(fr)
|
2021-11-05 |
2023-05-11 |
King Abdullah University Of Science And Technology |
Compositions d'immunisation de rappel de protéine de refocalisation et leurs méthodes d'utilisation
|
CA3237496A1
(fr)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Compositions de proteines de fusion immunogenes et leurs procedes d'utilisation
|
WO2023135515A1
(fr)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
WO2023161817A1
(fr)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
|
WO2023218322A1
(fr)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Procédé de production de formulations de vaccin avec des conservateurs
|
WO2024018061A1
(fr)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Utilisation de souches de bordetella pour le traitement de la bronchopneumopathie chronique obstructive
|